AIDS Therapies

Oral Formulation of BCX-34 Trial Begins in Humans

Published in AIDS Weekly, May 12th, 1997

BioCryst Pharmaceuticals, Birmingham, Alabama, announced the initiation of a Phase I feasibility study using an oral formulation of BCX-34 for the treatment of HIV in combination with standard antiretroviral therapy.

BCX-34 is a small-molecule drug that modulates the proliferation of T cells. Based on preclinical studies, scientists at the University of Alabama at Birmingham (UAB) and BioCryst theorize that BCX-34 may reduce HIV load in the bloodstream by inhibiting the replication of infected T cells.

The study, conducted under Michael S. Saag, M.D., UAB, is designed to obtain safety, pharmacology, and biological data.

"Plasma...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-05-12)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry